[1]李 冲,赵 云,王 昊,等.ICU鲍曼不动杆菌血流感染临床特征及预后危险因素分析[J].医学信息,2020,33(13):54-56,68.[doi:10.3969/j.issn.1006-1959.2020.13.015]
　LI Chong,ZHAO Yun,WANG Hao,et al.Clinical Characteristics and Prognostic Risk Factors of Bloodstream Infection of Acinetobacter Baumannii in ICU[J].Medical Information,2020,33(13):54-56,68.[doi:10.3969/j.issn.1006-1959.2020.13.015]
点击复制

ICU鲍曼不动杆菌血流感染临床特征及预后危险因素分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年13期
页码:
54-56,68
栏目:
论著
出版日期:
2020-07-01

文章信息/Info

Title:
Clinical Characteristics and Prognostic Risk Factors of Bloodstream Infection of Acinetobacter Baumannii in ICU
文章编号:
1006-1959（2020）13-0054-04
作者:
李 冲; 赵 云; 王 昊; 等
（1.山东省千佛山医院ICU二科，山东 济南 250014；2.东营市人民医院ICU二区，山东 东营 257091；3.山东大学齐鲁医院ICU，山东 济南 250117）
Author(s):
LI Chong; ZHAO Yun; WANG Hao; et al
(1.Second Department of ICU,Qianfoshan Hospital,Jinan 250014,Shandong,China;2.Second District ICU,Dongying People’s Hospital,Dongying 257091,Shandong,China;3.ICU of Qilu Hospital of Shandong University,Jinan 250117,Shandong,China)
关键词:
重症医学科; 鲍曼不动杆菌; 血流感染; 危险因素
Keywords:
Severe Medicine Department;  Acinetobacter baumannii;  Blood flow infection;  Risk factors
分类号:
R181.3
DOI:
10.3969/j.issn.1006-1959.2020.13.015
文献标志码:
A
摘要:
目的 分析山东省重症医学科（ICU）鲍曼不动杆菌血流感染患者预后的危险因素。方法 收集2015年1月~2019年12月山东大学齐鲁医院、山东省千佛医院、聊城市人民医院、东营市人民医院、山东省立三院ICU鲍曼不动杆菌血流感染患者125例临床资料，根据预后情况分为存活组（79例）与死亡组（46例）。分析人口学资料、基础疾病、糖皮质激素与免疫抑制剂使用情况、侵袭性操作、病情严重程度、细菌耐药情况，采用单因素、多因素Logistics回归分析的方法分析预后危险因素。结果 125例鲍曼不动杆菌血流感染患者中死亡46例，死亡率36.80%。单因素分析表明年龄、合并基础疾病＞3种、使用抗菌药物＞3种、侵袭性操作、糖皮质激素治疗、APACHEⅡ评分≥20分、住院时间≥30 d均为鲍曼不动杆菌血流感染患者死亡危险因素（P＜0.05）；多因素Logistic回归分析表明，合并基础疾病＞3种（OR=4.012，95%CI：2.366~5.455）、使用抗菌药物＞3种（OR=4.365，95%CI：3.152~5.231）、侵袭性操作（OR=2.654，95%CI：2.456~4.785）、糖皮质激素治疗（OR=5.154，95%CI：3.428~5.330）、急性生理学与慢性健康评分Ⅱ（APACHEⅡ）≥20分（OR=6.012，95%CI：3.545~7.364）是鲍曼不动杆菌血流感染患者死亡的独立危险因素。结论 ICU鲍曼不动杆菌血流感染患者死亡率较高，与合并基础疾病、使用抗菌药物种类、侵袭性操作、糖皮质激素治疗、APACHEⅡ评分相关，应加强对危险因素的评估，采取针对性的干预措施，以改善鲍曼不动杆菌血流感染患者的预后。
Abstract:
Objective To analyze the prognostic risk factors of patients with bloodstream infection of Acinetobacter baumannii in the Department of Intensive Medicine (ICU) of Shandong Province.Methods From January 2015 to December 2019, 125 clinical patients with bloodstream infection from ICU of Baumanii in Qilu Hospital of Shandong University, Qianfo Hospital of Shandong Province, Liaocheng People’s Hospital, Dongying City People’s Hospital, and Shandong Provincial Third Hospital were collected. The data were divided into survival group (79 cases) and death group (46 cases) according to prognosis. Analyze demographic data, underlying diseases, glucocorticoid and immunosuppressive use, invasive procedures, severity of disease, bacterial resistance, and use univariate and multivariate Logistic regression analysis to analyze prognostic risk factors. Results Of the 125 patients with Acinetobacter baumannii bloodstream infection, 46 died, with a mortality of 36.80%. Univariate analysis showed that age, combined underlying diseases＞ 3 types, use of antibacterial drugs＞ 3 types, invasive procedures, glucocorticoid therapy, APACHE II score ≥ 20 points,hospitalization time ≥ 30 d is a risk factor for death of patients with Acinetobacter baumannii bloodstream infection (P＜0.05);multivariate Logistic regression analysis showed that the combined underlying diseases were ＞3 (OR=4.012, 95%CI: 2.366~5.455), and the use of antibacterial drugs＞3 (OR=4.365,95%) CI: 3.152~5.231), invasive operation (OR=2.654, 95%CI: 2.456~4.785), glucocorticoid therapy (OR=5.154, 95%CI: 3.428~5.330), acute physiology and chronic health score Ⅱ (APACHE Ⅱ) ≥ 20 points (OR=6.012, 95%CI: 3.545~7.364) is an independent risk factor for death of patients with Acinetobacter baumannii bloodstream infection.Conclusion ICU Acinetobacter baumannii bloodstream infection patients have a higher mortality rate, which is related to the combination of underlying diseases, the use of antibacterial drugs, invasive procedures, glucocorticoid therapy, and APACHE Ⅱ score. The assessment of risk factors should be strengthened and targeted interventions should be taken to improve the prognosis of patients with Acinetobacter baumannii blood flow infection.

参考文献/References:

[1]Ulu-Kilic A,Gundogdu A,Cevahir F,et al.An outbreak of bloodstream infection due to extensively resistant Acinetobacter baumannii among neonates[J].Am J Infect Control,2018,46(2):154-158.[2]李娜,黄艳芳,唐喻莹,等.多重耐药鲍曼不动杆菌医院感染危险因素荟萃分析[J].中国感染控制杂志,2017,16(2):115-120.[3]Bi W,Liu H,Dunstan RA,et al.Extensively drug-resistant klebsiella pneumoniae causing nosocomial bloodstream Infections in China：molecular investigation of antibiotic resistance determinants，informing therapy，and clinical outcomes[J].Front Microbiol,2017(8):1230.[4]Aliyu S,Furuya Y,Larson E.Risk of subsequent health care-associated infection among patients with a bloodstream infection present on hospital admission[J].Am J Infect Control,2019,47(2):196-200.[5]Kwon KT,Oh WS,Song JH,et al.Impact of imipenem resistance on mortality in patients with Acinetobacter bacteraemia[J].J Antimiceob Chemother,2007,59(3):525-530.[6]陈佰义,何礼贤,胡必杰,等.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中华医学杂志,2012,92(2):76-85.[7]Knaus WA,Draper EA,Wanger DP,et al.APACHE Ⅱ: a severity of classification system[J].Crit Care Med,1985,13(40):818-829.[8]PA Wayne.Clinical and Laboratory Standards Institute.Performance Standards for Antimicrobial Susceptibility Testing[J].Sixteenth Infornational Supplement,2010,32(3):M100-S22.[9]陈春燕,黄冰冰,罗培燕,等.某综合ICU耐碳青霉烯鲍曼不动杆菌下呼吸道医院感染暴发调查[J].中国感染控制杂志,2016,15(5):341-343.[10]Park GE,Kang CI,Cha MK,et al.Bloodstream infections caused by Acinetobacter species with reduced susceptibility to tigecycline: clinical features and risk factors[J].Int J Infect Dis,2017(62):26-31.[11]Marki S,Mantadakis E,Mavromanolaki VE,et al.A 5-year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek Hospital[J].Infect Chemother,2016,48(3):190-198.[12]Kumar A,Randhawa VS,Nirupam N,et al.Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intenisve care unit, Delhi,India[J].J Infect Dev Ctries,2014,8(8):1049-1054.[13]胡宇睛,马新然,冒文君,等.鲍曼不动杆菌血流感染预后不良的危险因素[J].中国感染控制杂志,2018,17(4):329-334.[14]黄鹏,林洁,李克诚,等.55例鲍曼不动杆菌血流感染的临床分析[J].药物流行病学杂志,2016,25(8):507-510.[15]高婧,李伟,王昊,等.重症监护病房鲍曼不动杆菌血流感染发生率、菌株耐药性、抗菌药物使用及预后分析[J].中华传染病杂志,2017,35(4):232-234.[16]Park SY,Lee EJ,Kim T,et al.Early administration of appropriate antimicrobial agents to improve the outcome of carbapenem-resistant Acinetobacter baumannii complex bacteraemic pneumonia[J].Int Antimicrob Agents,2018,51(3):407-412.[17]Van BA,Halimi D,Bonetti EJ,et al.Meropenem/colistin synergy testing for multidurg-resistant Acinetobacter baunmannii strains by a two-dimensional gradient techniqur applicable in routine microbiology[J].J Antimicrob Chemother,2015,70(1):167-172.[18]张银维,周华,蔡洪流,等.鲍曼不动杆菌血流感染临床特征和死亡危险因素分析[J].中华内科杂志,2016,55(2):121-125.[19]曲俊彦,唐梅,陆杨,等.成人耐碳青霉烯革兰阴性菌血流感染临床特征及死亡危险因素分析[J].中国抗生素杂志,2017,42(3):212-217.[20]乔莉,张劲松,梅亚宁,等.鲍曼不动杆菌血流感染预后的危险因素分析[J].中华危重病急救医学,2013,25(8):471-474.

相似文献/References:

[1]李淑惠.鲍曼不动杆菌临床分布及耐药性分析[J].医学信息,2018,31(03):165.[doi:10.3969/j.issn.1006-1959.2018.03.061]
　LI Shu-hui.Clinical Distribution and Drug Resistance of Acinetobacter Baumannii[J].Medical Information,2018,31(13):165.[doi:10.3969/j.issn.1006-1959.2018.03.061]
[2]李佳颖,李春霖,王玉莹,等.鲍曼不动杆菌的单药治疗及其联合使用的研究[J].医学信息,2019,32(05):48.[doi:10.3969/j.issn.1006-1959.2019.05.016]
　LI Jia-ying,LI Chun-lin,WANG Yu-ying,et al.Monotherapy of Acinetobacter Baumannii and Its Combined Use[J].Medical Information,2019,32(13):48.[doi:10.3969/j.issn.1006-1959.2019.05.016]
[3]常 琪,魏韵佳,穆 琪,等.2016~2018年鲍曼不动杆菌临床分离株的 分布特征及耐药性变迁[J].医学信息,2019,32(16):119.[doi:10.3969/j.issn.1006-1959.2019.16.038]
　CHANG Qi,WEI Yun-jia,MU Qi,et al.Distribution Characteristics and Drug Resistance Changes of Clinical Isolates of Acinetobacter Baumannii from 2016 to 2018[J].Medical Information,2019,32(13):119.[doi:10.3969/j.issn.1006-1959.2019.16.038]
[4]李 晴.集束化护理在预防ICU患者呼吸机相关性肺炎发生的作用[J].医学信息,2020,33(14):187.[doi:10.3969/j.issn.1006-1959.2020.14.063]
　LI Qing.The Effect of Cluster Nursing on Preventing Ventilator-associated Pneumonia in ICU Patients[J].Medical Information,2020,33(13):187.[doi:10.3969/j.issn.1006-1959.2020.14.063]
[5]刘婕妤,杨文杰,赵学群.T淋巴细胞亚群对鲍曼不动杆菌感染与定植的诊断价值[J].医学信息,2021,34(20):167.[doi:10.3969/j.issn.1006-1959.2021.20.045]
　LIU Jie-yu,YANG Wen-jie,ZHAO Xue-qun.Diagnostic Value of T Lymphocyte Subsets in Acinetobacter Baumannii Infection and Colonization[J].Medical Information,2021,34(13):167.[doi:10.3969/j.issn.1006-1959.2021.20.045]
[6]陈金莲,刘泉波.鲍曼不动杆菌耐药机制及治疗现状的研究[J].医学信息,2022,35(03):45.[doi:10.3969/j.issn.1006-1959.2022.03.011]
　CHEN Jin-lian,LIU Quan-bo.Study on Drug Resistance Mechanism and Treatment Status of Acinetobacter Baumannii[J].Medical Information,2022,35(13):45.[doi:10.3969/j.issn.1006-1959.2022.03.011]
[7]兰 博,蓝桂伍,黄华田,等.肺泡灌洗液降钙素原在重症肺炎中的诊断价值[J].医学信息,2023,36(11):145.[doi:10.3969/j.issn.1006-1959.2023.11.030]
　LAN Bo,LAN Gui-wu,HUANG Hua-tian,et al.Diagnostic Value of Procalciton in Bronchoalveolar Fluid in Severe Pneumonia[J].Medical Information,2023,36(13):145.[doi:10.3969/j.issn.1006-1959.2023.11.030]

更新日期/Last Update: 1900-01-01